{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:05:28Z","timestamp":1789790728658,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.08.034","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:59:29Z","timestamp":1787669969000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage"],"prefix":"10.1016","author":[{"given":"Saumya Ranjan","family":"Satrusal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpon","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurava","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indranil","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muqtada Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhipsa","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0970-580X","authenticated-orcid":false,"given":"Shivansh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohini","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulranjan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1978-8251","authenticated-orcid":false,"given":"Aamir","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi Sankar","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-8543","authenticated-orcid":false,"given":"Dipak","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.08.034_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.08.034_bib2","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2026.08.034_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/modpathol.2010.200","article-title":"Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists","volume":"24","author":"Badve","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s43018-023-00535-w","article-title":"Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer","volume":"4","author":"Sun","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.034_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib6","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib7","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1038\/s41467-022-35059-x","article-title":"EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis","volume":"13","author":"Verma","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.034_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib9","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.08.034_bib10","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.08.034_bib11","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib13","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1016\/j.jfma.2022.05.015","article-title":"Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders","volume":"121","author":"Lin","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.ymthe.2026.08.034_bib14","first-page":"11","article-title":"Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins","volume":"15","author":"Ma","year":"2023","journal-title":"Breast Cancer (Dove Med. Press."},{"key":"10.1016\/j.ymthe.2026.08.034_bib15","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.08.034_bib16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","article-title":"Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial","volume":"31","author":"Jiang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2019.08.004","article-title":"Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer","volume":"20","author":"Fenn","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ymthe.2026.08.034_bib18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.08.034_bib19","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2408049121","article-title":"ACSL4-mediated H3K9 and H3K27 hyperacetylation upregulates SNAIL to drive TNBC metastasis","volume":"121","author":"Sinha","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.08.034_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsptsci.2c00100","article-title":"Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2","volume":"5","author":"Dale","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ymthe.2026.08.034_bib21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","article-title":"AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution","volume":"635","author":"Schade","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.08.034_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189253","article-title":"Emerging role of EZH2 in solid tumor metastasis","volume":"1880","author":"Verma","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.034_bib23","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/epi-2022-0320","article-title":"Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects","volume":"14","author":"Huang","year":"2022","journal-title":"Epigenomics"},{"key":"10.1016\/j.ymthe.2026.08.034_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/13543776.2023.2206018","article-title":"A patent review of EZH2 inhibitors from 2017 and beyond","volume":"33","author":"Wan","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ymthe.2026.08.034_bib25","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.21037\/gs-21-505","article-title":"The expression and potential mechanism of EGFR and EZH2 in breast cancer","volume":"10","author":"Tang","year":"2021","journal-title":"Gland Surg."},{"key":"10.1016\/j.ymthe.2026.08.034_bib26","article-title":"Epidermal growth factor receptor (EGFR) overexpression in triple-negative breast cancer: association with clinicopathologic features and prognostic parameters","volume":"2","author":"Hashmi","year":"2019","journal-title":"Surg. Exp. Pathol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib27","doi-asserted-by":"crossref","first-page":"73618","DOI":"10.18632\/oncotarget.12037","article-title":"Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer","volume":"7","author":"El Guerrab","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2026.08.034_bib28","article-title":"Busting the Breast Cancer with AstraZeneca's Gefitinib","volume":"2023","author":"Chemmalar","year":"2023","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"10.1016\/j.ymthe.2026.08.034_bib29","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/modpathol.2013.251","article-title":"High EGFR gene copy number predicts poor outcome in triple-negative breast cancer","volume":"27","author":"Park","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib30","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Sordella","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.08.034_bib31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrclinonc.2010.154","article-title":"Triple-negative breast cancer: disease entity or title of convenience?","volume":"7","author":"Carey","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/modpathol.3800438","article-title":"EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations","volume":"18","author":"Bhargava","year":"2005","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib33","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.08.034_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ymthe.2026.08.034_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1042\/BST20191055","article-title":"Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis","volume":"48","author":"Lev","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ymthe.2026.08.034_bib36","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2012.46.2408","article-title":"Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer","volume":"31","author":"Baselga","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib37","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","article-title":"TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer","volume":"30","author":"Carey","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.2042-7158.2010.01236.x","article-title":"Dual inhibition: a novel promising pharmacological approach for different disease conditions","volume":"63","author":"Patyar","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib39","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5474","article-title":"Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation","volume":"62","author":"Wang","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.08.034_bib41","first-page":"422","article-title":"EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2\/-9 pathway","volume":"8","author":"Chien","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrclinonc.2010.97","article-title":"Understanding resistance to EGFR inhibitors-impact on future treatment strategies","volume":"7","author":"Wheeler","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-1-0716-3052-5_22","article-title":"Transwell In Vitro Cell Migration and Invasion Assays","volume":"2644","author":"Justus","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib44","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3389\/fonc.2020.01195","article-title":"Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model","volume":"10","author":"Schr\u00f6rs","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/1535-7163.MCT-04-0329","article-title":"Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor","volume":"4","author":"McKillop","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2026.08.034_bib46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ame2.12139","article-title":"Clinical hematological and biochemical parameters in Swiss, BALB\/c, C57BL\/6 and B6D2F1 Mus musculus","volume":"3","author":"Silva-Santana","year":"2020","journal-title":"Anim. Model. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.08.034_bib47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.08.034_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.ymthe.2026.08.034_bib49","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","article-title":"FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer","volume":"22","author":"Kazandjian","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib50","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1200\/JCO.2005.08.326","article-title":"Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib51","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022613","article-title":"The efficacy of gefitinib supplementation for breast cancer: A meta-analysis of randomized controlled studies","volume":"99","author":"Ye","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymthe.2026.08.034_bib52","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.2147\/OTT.S186498","article-title":"Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells","volume":"11","author":"Yang","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.ymthe.2026.08.034_bib53","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.4161\/15384047.2014.972776","article-title":"EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells","volume":"15","author":"Katona","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.034_bib54","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1186\/s12885-020-07667-7","article-title":"EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells","volume":"20","author":"Gong","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ymthe.2026.08.034_bib55","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1080\/15548627.2020.1851492","article-title":"PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1)","volume":"17","author":"Luo","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.ymthe.2026.08.034_bib56","first-page":"4885","article-title":"Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase","volume":"6","author":"Sirotnak","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib57","article-title":"Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy","volume":"5","author":"Dheeraj","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.08.034_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2318093121","article-title":"A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer","volume":"121","author":"Cencic","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.08.034_bib59","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.7150\/ijbs.94058","article-title":"Dysregulated Ribosome Biogenesis Is a Targetable Vulnerability in Triple-Negative Breast Cancer: MRPS27 as a Key Mediator of the Stemness-inhibitory Effect of Lovastatin","volume":"20","author":"Zheng","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ymthe.2026.08.034_bib60","first-page":"3496","article-title":"Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)","volume":"8","author":"Heimberger","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib61","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/toxres\/tfab008","article-title":"Comparison of gefitinib-induced skin adverse reactions (SAR) in C57BL\/6 and FVB\/N mice","volume":"10","author":"Zhang","year":"2021","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib62","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Sulforhodamine B colorimetric assay for cytotoxicity screening","volume":"1","author":"Vichai","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2026.08.034_bib63","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2026.08.034_bib64","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.034_bib65","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.034_bib66","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","article-title":"A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology","volume":"3","author":"Guillen","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.034_bib67","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.ymthe.2025.12.056","article-title":"Discovery, preclinical safety, and efficacy characterization of SMAC mimetic S-016-1348 as a potential cancer therapeutic","volume":"34","author":"Sinha","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.034_bib68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13287-022-02902-3","article-title":"Assay establishment and validation of a high-throughput organoid-based drug screening platform","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ymthe.2026.08.034_bib69","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nn.2580","article-title":"In situ visualization and dynamics of newly synthesized proteins in rat hippocampal neurons","volume":"13","author":"Dieterich","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2026.08.034_bib70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1083\/jcb.201112145","article-title":"Nuclear translation visualized by ribosome-bound nascent chain puromycylation","volume":"197","author":"David","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.08.034_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baab007","article-title":"bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses","volume":"2021","author":"J\u00e9z\u00e9quel","year":"2021","journal-title":"Database."},{"key":"10.1016\/j.ymthe.2026.08.034_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib73","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","article-title":"Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups","volume":"567","author":"Rueda","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.08.034_bib74","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.034_bib75","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.08.034_bib76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ymthe.2026.08.034_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6","article-title":"Automated docking of flexible ligands: applications of AutoDock","volume":"9","author":"Goodsell","year":"1996","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.ymthe.2026.08.034_bib78","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ymthe.2026.08.034_bib79","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ymthe.2026.08.034_bib80","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/ct700301q","article-title":"GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ymthe.2026.08.034_bib81","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ymthe.2026.08.034_bib82","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/prot.22711","article-title":"Improved side-chain torsion potentials for the Amber ff99SB protein force field","volume":"78","author":"Lindorff-Larsen","year":"2010","journal-title":"Proteins"},{"key":"10.1016\/j.ymthe.2026.08.034_bib83","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1756-0500-5-367","article-title":"ACPYPE - AnteChamber PYthon Parser interfacE","volume":"5","author":"Sousa da Silva","year":"2012","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.ymthe.2026.08.034_bib84","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ymthe.2026.08.034_bib85","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: A linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ymthe.2026.08.034_bib86","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: An N\u22c5log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ymthe.2026.08.034_bib87","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ymthe.2026.08.034_bib88","series-title":"XMGRACE, Version 5.1. 19","author":"Turner","year":"2005"},{"key":"10.1016\/j.ymthe.2026.08.034_bib89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.ymthe.2026.08.034_bib90","series-title":"The PyMOL Molecular Graphics System, Version 3.0","author":"Schrodinger","year":"2015"},{"key":"10.1016\/j.ymthe.2026.08.034_bib91","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ymthe.2026.08.034_bib92","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.08.034_bib93","series-title":"EnhancedVolcano: publication-ready volcano plots with enhanced colouring and labeling. R. package version 1.8. 0","author":"Blighe","year":"2020"},{"key":"10.1016\/j.ymthe.2026.08.034_bib94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2105-12-35","article-title":"VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R","volume":"12","author":"Chen","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.08.034_bib95","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.ymthe.2026.08.034_bib96","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1093\/bioinformatics\/btu393","article-title":"circlize Implements and enhances circular visualization in R","volume":"30","author":"Gu","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.08.034_bib97","series-title":"pheatmap: Pretty Heatmaps. R package version 1.0. 12","author":"Kolde","year":"2019"},{"key":"10.1016\/j.ymthe.2026.08.034_bib98","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/00498254.2022.2101033","article-title":"Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-1559","volume":"52","author":"Verma","year":"2022","journal-title":"Xenobiotica."},{"key":"10.1016\/j.ymthe.2026.08.034_bib99","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/00498254.2023.2265475","article-title":"Preclinical pharmacokinetic exploration of a novel osteoporotic quinazolinone-benzopyran-indole hybrid (S019-0385) using LC-MS\/MS","volume":"53","author":"Kumar","year":"2023","journal-title":"Xenobiotica."},{"key":"10.1016\/j.ymthe.2026.08.034_bib100","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/1389200224666230817101950","article-title":"Preclinical Pharmacokinetics and CYP Modulation Activity of Chebulinic Acid: A Potent Molecule Against Metabolic Disease","volume":"24","author":"Biswas","year":"2023","journal-title":"Curr. Drug Metab."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600715X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600715X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:36:51Z","timestamp":1789789011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162600715X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":100,"alternative-id":["S152500162600715X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.034","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}